Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 589
- Registration Number
- NCT06346392
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Akeso
- Target Recruit Count
- 506
- Registration Number
- NCT06341335
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 468
- Registration Number
- NCT06340568
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 500
- Registration Number
- NCT06333951
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya-shi, Aichi, Japan
🇺🇸Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Target Recruit Count
- 45
- Registration Number
- NCT06323460
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Bio-Thera Solutions
- Target Recruit Count
- 140
- Registration Number
- NCT06321068
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT06320405
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT06317311
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT06318897
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.